Abstract
Gastrointestinal (GI) tumors are a leading cause of cancer-related deaths in the world. In fact, gastric cancer (GC) is the third cause of cancer deaths, whereas aesophageal neoplasm is the eighth most common cancer worldwide and its incidence, especially adenocarcinoma type, is continuously increasing. Also Hepatocellular carcinoma, Cholangiocarcinoma and pancreatic cancer represent a very interesting model to multidisciplinary approach and recently new drugs are used in their treatment. Currently, new clinical trials are designed including classic chemotherapy in association with either small molecule inhibitors (i.e. Tyrosine Kinase inhibitors) and/or monoclonal antibody (i.e. anti-EGFR antibody). Moreover, a comphrensive list of new molecules for target therapy is included in this issue. The development of new treatment modalities (multidisciplinary approach) and targeted therapy approaches, have contributed to improve the outcome in these cancer diseases. Our expanding knowledge of the molecular biology of malignancy, the related identification of therapeutically-important targets, and the subsequent development of systemic agents that inhibit critical kinases and pathways, have all contributed to great excitement and progress in cancer treatment.
| Original language | English |
|---|---|
| Journal | Current Cancer Drug Targets |
| DOIs | |
| Publication status | Published - 2018 |
Fingerprint
Cite this
The Role of Target Therapy in the Treatment of Gastrointestinal Non Colorectal Cancers : Clinical Impact and Cost Consideration. / Berretta, Massimiliano; Di Francia, Raffaele; De Diviitis, Chiara; Nasti, Guglielmo; Canzonieri, Vincenzo; Caraglia, Michele; Facchini, Gaetano; Tirelli, Umberto.
In: Current Cancer Drug Targets, 2018.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The Role of Target Therapy in the Treatment of Gastrointestinal Non Colorectal Cancers
T2 - Clinical Impact and Cost Consideration
AU - Berretta, Massimiliano
AU - Di Francia, Raffaele
AU - De Diviitis, Chiara
AU - Nasti, Guglielmo
AU - Canzonieri, Vincenzo
AU - Caraglia, Michele
AU - Facchini, Gaetano
AU - Tirelli, Umberto
N1 - Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
PY - 2018
Y1 - 2018
N2 - Gastrointestinal (GI) tumors are a leading cause of cancer-related deaths in the world. In fact, gastric cancer (GC) is the third cause of cancer deaths, whereas aesophageal neoplasm is the eighth most common cancer worldwide and its incidence, especially adenocarcinoma type, is continuously increasing. Also Hepatocellular carcinoma, Cholangiocarcinoma and pancreatic cancer represent a very interesting model to multidisciplinary approach and recently new drugs are used in their treatment. Currently, new clinical trials are designed including classic chemotherapy in association with either small molecule inhibitors (i.e. Tyrosine Kinase inhibitors) and/or monoclonal antibody (i.e. anti-EGFR antibody). Moreover, a comphrensive list of new molecules for target therapy is included in this issue. The development of new treatment modalities (multidisciplinary approach) and targeted therapy approaches, have contributed to improve the outcome in these cancer diseases. Our expanding knowledge of the molecular biology of malignancy, the related identification of therapeutically-important targets, and the subsequent development of systemic agents that inhibit critical kinases and pathways, have all contributed to great excitement and progress in cancer treatment.
AB - Gastrointestinal (GI) tumors are a leading cause of cancer-related deaths in the world. In fact, gastric cancer (GC) is the third cause of cancer deaths, whereas aesophageal neoplasm is the eighth most common cancer worldwide and its incidence, especially adenocarcinoma type, is continuously increasing. Also Hepatocellular carcinoma, Cholangiocarcinoma and pancreatic cancer represent a very interesting model to multidisciplinary approach and recently new drugs are used in their treatment. Currently, new clinical trials are designed including classic chemotherapy in association with either small molecule inhibitors (i.e. Tyrosine Kinase inhibitors) and/or monoclonal antibody (i.e. anti-EGFR antibody). Moreover, a comphrensive list of new molecules for target therapy is included in this issue. The development of new treatment modalities (multidisciplinary approach) and targeted therapy approaches, have contributed to improve the outcome in these cancer diseases. Our expanding knowledge of the molecular biology of malignancy, the related identification of therapeutically-important targets, and the subsequent development of systemic agents that inhibit critical kinases and pathways, have all contributed to great excitement and progress in cancer treatment.
U2 - 10.2174/1568009617666170208162058
DO - 10.2174/1568009617666170208162058
M3 - Article
C2 - 28183250
JO - Current Cancer Drug Targets
JF - Current Cancer Drug Targets
SN - 1568-0096
ER -